CARDIOASPIRIN 100 mg Compresse gastroresistenti

DRUG3 trials

Sponsors

Fondazione IRCCS Istituto Nazionale Dei Tumori, Fondazione Toscana Gabriele Monasterio, Azienda Ospedaliera Universitaria Gaetano Martino Messina

Conditions

Chronic Coronary Syndrome in patients undergoing percutaneous coronary intervention (PCI)Patients with atrial fibrillation undergoing percutaneous left atrial appendage closure with the Amulet deviceSubjects at high risk of inflammatory state and mortality from lung cancerother cancers and all causes

Phase 2

A randomized trial of multi-factorial primary prevention in high risk subjects candidate to a lung cancer early detection CT program

Not yet recruitingCTIS2024-513660-26-00

Fondazione IRCCS Istituto Nazionale Dei TumoriSubjects at high risk of inflammatory state and mortality from lung cancer, other cancers and all causes

Target: 2000Updated: 2024-08-05

Phase 3

A Randomized Controlled Study Evaluating Short-Term Dual Antiplatelet Therapy with Low-Dose Ticagrelor (60 mg) Followed by Monotherapy versus Standard-Duration Dual Antiplatelet Therapy with Clopidogrel in Patients with Chronic Coronary Syndrome Undergoing Percutaneous Coronary Intervention: the STELAR trial

Not yet recruitingCTIS2026-526368-18-00

Azienda Ospedaliera Universitaria Gaetano Martino MessinaChronic Coronary Syndrome in patients undergoing percutaneous coronary intervention (PCI)

Target: 500Updated: 2026-07-27

Phase 4

Head-to-head compaRison of single versus dual antiplatelet treatMent strategY after percutaneous left atrial appenDage closure: A MULticenter, randomizEd sTudy. The ARMYDA-AMULET study

RecruitingCTIS2024-515361-34-00

Fondazione Toscana Gabriele MonasterioPatients with atrial fibrillation undergoing percutaneous left atrial appendage closure with the Amulet device

Start: 2021-10-13Target: 606Updated: 2025-12-19